Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

P Osterlund, T Ruotsalainen, R Korpela, M Saxelin, A Ollus, P Valta, M Kouri, I Elomaa, H Joensuu, P Osterlund, T Ruotsalainen, R Korpela, M Saxelin, A Ollus, P Valta, M Kouri, I Elomaa, H Joensuu

Abstract

5-Fluorouracil (5-FU)-based chemotherapy is frequently associated with diarrhoea. We compared two 5-FU-based regimens and the effect of Lactobacillus and fibre supplementation on treatment tolerability. Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy. On the basis of random allocation, the study participants did or did not receive Lactobacillus rhamnosus GG supplementation (1-2 x 10(10) per day) and fibre (11 g guar gum per day) during chemotherapy. Patients who received Lactobacillus had less grade 3 or 4 diarrhoea (22 vs 37%, P=0.027), reported less abdominal discomfort, needed less hospital care and had fewer chemotherapy dose reductions due to bowel toxicity. No Lactobacillus-related toxicity was detected. Guar gum supplementation had no influence on chemotherapy tolerability. The simplified de Gramont regimen was associated with fewer grade 3 or 4 adverse effects than the Mayo regimen (45 vs 89%), and with less diarrhoea. We conclude that Lactobacillus GG supplementation is well tolerated and may reduce the frequency of severe diarrhoea and abdominal discomfort related to 5-FU-based chemotherapy.

Figures

Figure 1
Figure 1
Effect of oral Lactobacillus rhamnosus GG (L) and Lactobacillus rhamnosus GG plus fibre (guar gum, L+F) supplementation on adverse events recorded during 5-FU-based chemotherapy.

References

    1. Alam NH, Meier R, Schneider H, Sarker SA, Bardhan PK, Mahalanabis D, Fuchs GJ, Gyr N (2000) Partially hydrolyzed guar gum-supplemented oral rehydration solution in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr 31: 503–507
    1. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer I (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351
    1. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Billiau V, Buyse M, Gramont A (2001) Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies. Semin Oncol 28: 35–40
    1. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896–2903
    1. Anonymous (1996) Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group. Ann Surg Oncol 3: 423–430
    1. Banasaz M, Norin E, Holma R, Midtvedt T (2002) Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillusrhamnosus GG. Appl Environ Microbiol 68: 3031–3034
    1. Carde P, Cosset-Delaigue M, Laplanche A, Chareau I (1989) Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. Eur J Cancer Clin Oncol 25: 939–944
    1. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, Gasbarrini A (2002) Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 16: 1461–1467
    1. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997a) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808–815
    1. de Gramont A, Louvet C, André T (1997b) A simplified bimonthly regimen with leucovorin (LV) and 5-fluorouracil (5-FU) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 16: A1019
    1. Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C, Famularo G (2002) Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 97: 2150–2152
    1. Freedman LS, White SJ (1976) On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32: 691–694
    1. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons Jr RJ, Pemberton JH, Wolff BG (1992) Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 174: 27–32
    1. Gleeson NC, Fiorica JV, Mark JE, Pinelli DM, Hoffman MS, Roberts WS, Cavanagh D (1993) Externalized Groshong catheters and Hickman ports for central venous access in gynecologic oncology patients. Gynecol Oncol 51: 372–376
    1. Homann HH, Kemen M, Fuessenich C, Senkal M, Zumtobel V (1994) Reduction in diarrhea incidence by soluble fiber in patients receiving total or supplemental enteral nutrition. J Parenter Enteral Nutr 18: 486–490
    1. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ (2002) Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 47: 2625–2634
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: 638–646
    1. Kerr DJ (2001) A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results. Semin Oncol 28: 31–34
    1. Khaled Z, Guandalini S, Hendrickson BA (2003) Filtered supernatant of Lactobacillus GG (LGG) and VSL#3 prevent Crohn's diasese (CD) mucosa adherent –E. coli -induced degradation of tight junctions (TJ) associated proteins occludin and Zo-1. J Pediatr Gastroenterol Nutr 36: 520
    1. Kock H, Pietsch M, Krause U, Wilke H, Eigler F (1998) Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22: 12–16
    1. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ, European Organization of R and Treatment of Cancer Gastrointestinal Group S (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-h infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21: 3721–3728
    1. Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C, Pater J, Shepherd L, Zee B, Seitz JF, Milan C, Pignon JP (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: 939–944
    1. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA (2003) Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells invitro. Gut 52: 827–833
    1. Mattar AF, Drongowski RA, Coran AG, Harmon CM (2001) Effect of probiotics on enterocyte bacterial translocation invitro. Pediatr Surg Int 17: 265–268
    1. Meier R, Beglinger C, Schneider H, Rowedder A, Gyr K (1993) Effect of a liquid diet with and without soluble fiber supplementation on intestinal transit and cholecystokinin release in volunteers. J Parenter Enteral Nutr 17: 231–235
    1. Meier R, Burri E, Steuerwald M (2003) The role of nutrition in diarrhoea syndromes. Curr Opin Clin Nutr Metab Care 6: 563–567
    1. O'Connell M, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502–507
    1. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons Jr RJ, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295–300
    1. Ouwehand AC, Salminen S, Isolauri E (2002) Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 82: 279–289
    1. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA: Cancer J Clin 49(1): 33–64
    1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18–29
    1. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103–115
    1. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88: 1859–1865
    1. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S (1988) Preservation of intestinal integrity during radiotherapy using live Lactobacillusacidophilus cultures. Clin Radiol 39: 435–437
    1. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, Jarvinen A (2004) Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. Rhamnosus GG. Clin Infect Dis 38: 62–69
    1. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W (2001) Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 138: 361–365
    1. Tao Y, Drabik KA, Waypa TS, Musch MW, Alverdy JC, Schneewind O, Chang EB, Petrof EO (2006) Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol 290: C1018–C1030
    1. Urbancsek H, Kazar T, Mezes I, Neumann K (2001) Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 13: 391–396
    1. Vaarala O (2003) Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy 33: 1634–1640
    1. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ (2002) Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 38: 1429–1436
    1. Von Bultzingslowen I, Adlerberth I, Wold AE, Dahlen G, Jontell M (2003) Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol Immunol 18: 278–284
    1. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17: 3553–3559
    1. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB (2007) Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132: 562–575

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever